Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 265

1.

RANBP9 affects cancer cells response to genotoxic stress and its overexpression is associated with worse response to platinum in NSCLC patients.

Tessari A, Parbhoo K, Pawlikowski M, Fassan M, Rulli E, Foray C, Fabbri A, Embrione V, Ganzinelli M, Capece M, Campbell MJ, Broggini M, La Perle K, Farina G, Cole S, Marabese M, Hernandez M, Amann JM, Pruneri G, Carbone DP, Garassino MC, Croce CM, Palmieri D, Coppola V.

Oncogene. 2018 Aug 3. doi: 10.1038/s41388-018-0424-8. [Epub ahead of print]

PMID:
30076413
2.

RELEVENT Trial: Phase II Trial of Ramucirumab, Carboplatin, and Paclitaxel in Previously Untreated Thymic Carcinoma/B3 Thymoma With Area of Carcinoma.

Imbimbo M, Vitali M, Fabbri A, Ottaviano M, Pasello G, Petrini I, Palmieri G, Berardi R, Zucali P, Ganzinelli M, Marabese M, Broggini M, Marino M, Trama A, Rulli E, Hollander L, Pruneri G, Torri V, Garassino MC.

Clin Lung Cancer. 2018 Jul 3. pii: S1525-7304(18)30164-5. doi: 10.1016/j.cllc.2018.06.005. [Epub ahead of print]

PMID:
30033090
3.

Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models.

Del Curatolo A, Conciatori F, Cesta Incani U, Bazzichetto C, Falcone I, Corbo V, D'Agosto S, Eramo A, Sette G, Sperduti I, De Luca T, Marabese M, Shirasawa S, De Maria R, Scarpa A, Broggini M, Del Bufalo D, Cognetti F, Milella M, Ciuffreda L.

J Exp Clin Cancer Res. 2018 Jul 9;37(1):140. doi: 10.1186/s13046-018-0820-5.

4.

Identification of small-molecule EGFR allosteric inhibitors by high-throughput docking.

Caporuscio F, Tinivella A, Restelli V, Semrau MS, Pinzi L, Storici P, Broggini M, Rastelli G.

Future Med Chem. 2018 Jul 1;10(13):1545-1553. doi: 10.4155/fmc-2018-0063. Epub 2018 May 16.

PMID:
29766737
5.

Wee1 inhibitor MK1775 sensitizes KRAS mutated NSCLC cells to sorafenib.

Caiola E, Frapolli R, Tomanelli M, Valerio R, Iezzi A, Garassino MC, Broggini M, Marabese M.

Sci Rep. 2018 Jan 17;8(1):948. doi: 10.1038/s41598-017-18900-y.

6.

PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy.

Tarantelli C, Gaudio E, Arribas AJ, Kwee I, Hillmann P, Rinaldi A, Cascione L, Spriano F, Bernasconi E, Guidetti F, Carrassa L, Pittau RB, Beaufils F, Ritschard R, Rageot D, Sele A, Dossena B, Rossi FM, Zucchetto A, Taborelli M, Gattei V, Rossi D, Stathis A, Stussi G, Broggini M, Wymann MP, Wicki A, Zucca E, Cmiljanovic V, Fabbro D, Bertoni F.

Clin Cancer Res. 2018 Jan 1;24(1):120-129. doi: 10.1158/1078-0432.CCR-17-1041. Epub 2017 Oct 24.

PMID:
29066507
7.

Combination of paclitaxel, bevacizumab and MEK162 in second line treatment in platinum-relapsing patient derived ovarian cancer xenografts.

Ricci F, Guffanti F, Damia G, Broggini M.

Mol Cancer. 2017 May 30;16(1):97. doi: 10.1186/s12943-017-0662-3.

8.

Multi-Chemotherapeutic Schedules Containing the pan-FGFR Inhibitor ARQ 087 are Safe and Show Antitumor Activity in Different Xenograft Models.

Chilà R, Hall G T, Abbadessa G, Broggini M, Damia G.

Transl Oncol. 2017 Apr;10(2):153-157. doi: 10.1016/j.tranon.2016.12.003. Epub 2017 Feb 3.

9.

The 5'UTR variant of ERCC5 fails to influence outcomes in ovarian and lung cancer patients undergoing treatment with platinum-based drugs.

Rulli E, Guffanti F, Caiola E, Ganzinelli M, Damia G, Garassino MC, Piva S, Ceppi L, Broggini M, Marabese M.

Sci Rep. 2016 Dec 14;6:39217. doi: 10.1038/srep39217.

10.

Probing an Allosteric Pocket of CDK2 with Small Molecules.

Christodoulou MS, Caporuscio F, Restelli V, Carlino L, Cannazza G, Costanzi E, Citti C, Lo Presti L, Pisani P, Battistutta R, Broggini M, Passarella D, Rastelli G.

ChemMedChem. 2017 Jan 5;12(1):33-41. doi: 10.1002/cmdc.201600474. Epub 2016 Dec 19.

PMID:
27860401
11.

Activity of Pan-Class I Isoform PI3K/mTOR Inhibitor PF-05212384 in Combination with Crizotinib in Ovarian Cancer Xenografts and PDX.

Iezzi A, Caiola E, Broggini M.

Transl Oncol. 2016 Oct;9(5):458-465. doi: 10.1016/j.tranon.2016.08.011.

12.

To investigate the degenerative alterations of the spine in Paleopathology.

Licata M, Armocida G, Broggini M, Borgo M.

Acta Reumatol Port. 2017 Jan-Mar;42(1):94-95.

13.

In vivo effect of copper status on cisplatin-induced nephrotoxicity.

Puchkova LV, Skvortsov AN, Rusconi P, Ilyechova EY, Broggini M.

Biometals. 2016 Oct;29(5):841-9. doi: 10.1007/s10534-016-9955-z. Epub 2016 Aug 1.

PMID:
27481100
14.

Comparative metabolomics profiling of isogenic KRAS wild type and mutant NSCLC cells in vitro and in vivo.

Brunelli L, Caiola E, Marabese M, Broggini M, Pastorelli R.

Sci Rep. 2016 Jun 22;6:28398. doi: 10.1038/srep28398.

15.

Different metabolic responses to PI3K inhibition in NSCLC cells harboring wild-type and G12C mutant KRAS.

Caiola E, Brunelli L, Marabese M, Broggini M, Lupi M, Pastorelli R.

Oncotarget. 2016 Aug 9;7(32):51462-51472. doi: 10.18632/oncotarget.9849.

16.

Can the response to a platinum-based therapy be predicted by the DNA repair status in non-small cell lung cancer?

Macerelli M, Ganzinelli M, Gouedard C, Broggini M, Garassino MC, Linardou H, Damia G, Wiesmüller L.

Cancer Treat Rev. 2016 Jul;48:8-19. doi: 10.1016/j.ctrv.2016.05.004. Epub 2016 May 24. Review.

PMID:
27262017
17.

G48A, a New KRAS Mutation Found in Lung Adenocarcinoma.

Marabese M, Caiola E, Garassino MC, Rastelli G, Settanni G, Brugnara S, Broggini M, Ganzinelli M.

J Thorac Oncol. 2016 Jul;11(7):1170-5. doi: 10.1016/j.jtho.2016.03.013. Epub 2016 Apr 4.

18.

Class II phosphoinositide 3-kinase C2β regulates a novel signaling pathway involved in breast cancer progression.

Chikh A, Ferro R, Abbott JJ, Piñeiro R, Buus R, Iezzi M, Ricci F, Bergamaschi D, Ostano P, Chiorino G, Lattanzio R, Broggini M, Piantelli M, Maffucci T, Falasca M.

Oncotarget. 2016 Apr 5;7(14):18325-45. doi: 10.18632/oncotarget.7761.

19.

Characterization of MTAP Gene Expression in Breast Cancer Patients and Cell Lines.

de Oliveira SF, Ganzinelli M, Chilà R, Serino L, Maciel ME, Urban Cde A, de Lima RS, Cavalli IJ, Generali D, Broggini M, Damia G, Ribeiro EM.

PLoS One. 2016 Jan 11;11(1):e0145647. doi: 10.1371/journal.pone.0145647. eCollection 2016.

20.

Role of KRAS-LCS6 polymorphism in advanced NSCLC patients treated with erlotinib or docetaxel in second line treatment (TAILOR).

Ganzinelli M, Rulli E, Caiola E, Garassino MC, Broggini M, Copreni E, Piva S, Longo F, Labianca R, Bareggi C, Fabbri MA, Martelli O, Fagnani D, Locatelli MC, Bertolini A, Valmadre G, Pavese I, Calcagno A, Sarobba MG, Marabese M.

Sci Rep. 2015 Nov 17;5:16331. doi: 10.1038/srep16331.

21.

KRAS mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapy.

Marabese M, Ganzinelli M, Garassino MC, Shepherd FA, Piva S, Caiola E, Macerelli M, Bettini A, Lauricella C, Floriani I, Farina G, Longo F, Bonomi L, Fabbri MA, Veronese S, Marsoni S, Broggini M, Rulli E.

Oncotarget. 2015 Oct 20;6(32):34014-22. doi: 10.18632/oncotarget.5607.

22.

Base excision repair-mediated resistance to cisplatin in KRAS(G12C) mutant NSCLC cells.

Caiola E, Salles D, Frapolli R, Lupi M, Rotella G, Ronchi A, Garassino MC, Mattschas N, Colavecchio S, Broggini M, Wiesmüller L, Marabese M.

Oncotarget. 2015 Oct 6;6(30):30072-87. doi: 10.18632/oncotarget.5019.

23.

∆Np73beta induces caveolin-1 in human non-small cell lung cancer cell line H1299.

Caiola E, Marrazzo E, Alesci S, Broggini M, Marabese M.

Tumour Biol. 2016 Feb;37(2):2015-21. doi: 10.1007/s13277-015-4012-z. Epub 2015 Sep 4.

PMID:
26337278
24.

Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trial.

Rulli E, Marabese M, Torri V, Farina G, Veronese S, Bettini A, Longo F, Moscetti L, Ganzinelli M, Lauricella C, Copreni E, Labianca R, Martelli O, Marsoni S, Broggini M, Garassino MC; TAILOR trialists.

Ann Oncol. 2015 Oct;26(10):2079-84. doi: 10.1093/annonc/mdv318. Epub 2015 Jul 24.

PMID:
26209642
25.

Correction to Lancet Oncol 2015; 16: 747. EGFR mutations and EGFR tyrosine kinase inhibitors.

Torri V, Broggini M, Garassino MC.

Lancet Oncol. 2015 Jul;16(7):e313. doi: 10.1016/S1470-2045(15)00082-0. No abstract available.

PMID:
26149882
26.

EGFR mutations and EGFR tyrosine kinase inhibitors.

Torri V, Broggini M, Garassino MC.

Lancet Oncol. 2015 Jul;16(7):746-8. doi: 10.1016/S1470-2045(15)00028-5. Epub 2015 Jun 4. No abstract available. Erratum in: Lancet Oncol. 2015 Jul;16(7):e313.

PMID:
26051233
27.

Germ cell tumors overexpress the candidate therapeutic target cyclin B1 independently of p53 function.

De Giorgi U, Yuan J, Moroni M, Veronese S, Sartore-Bianchi A, Broggini M, Rosti G, Strebhardt K, Ruffini PA.

Int J Biol Markers. 2015 Jul 22;30(3):e275-81. doi: 10.5301/jbm.5000149.

PMID:
25982682
28.
29.

Available evidence and new biological perspectives on medical treatment of advanced thymic epithelial tumors.

Serpico D, Trama A, Haspinger ER, Agustoni F, Botta L, Berardi R, Palmieri G, Zucali P, Gallucci R, Broggini M, Gatta G, Pastorino U, Pelosi G, de Braud F, Garassino MC; TYME (TYmic MalignanciEs) Collaborative Group.

Ann Oncol. 2015 May;26(5):838-47. doi: 10.1093/annonc/mdu527. Epub 2014 Nov 19. Review.

PMID:
25411417
30.

Direct but not indirect co-culture with osteogenically differentiated human bone marrow stromal cells increases RANKL/OPG ratio in human breast cancer cells generating bone metastases.

Arrigoni C, De Luca P, Gilardi M, Previdi S, Broggini M, Moretti M.

Mol Cancer. 2014 Oct 21;13:238. doi: 10.1186/1476-4598-13-238.

31.

Benzylidenetetralones, cyclic chalcone analogues, induce cell cycle arrest and apoptosis in HCT116 colorectal cancer cells.

Drutovic D, Chripkova M, Pilatova M, Kruzliak P, Perjesi P, Sarissky M, Lupi M, Damia G, Broggini M, Mojzis J.

Tumour Biol. 2014 Oct;35(10):9967-75. doi: 10.1007/s13277-014-2289-y. Epub 2014 Jul 10.

PMID:
25008568
32.

Genetic markers for prediction of treatment outcomes in ovarian cancer.

Caiola E, Broggini M, Marabese M.

Pharmacogenomics J. 2014 Oct;14(5):401-10. doi: 10.1038/tpj.2014.32. Epub 2014 Jul 8. Review.

PMID:
25001881
33.

Capturing the metabolomic diversity of KRAS mutants in non-small-cell lung cancer cells.

Brunelli L, Caiola E, Marabese M, Broggini M, Pastorelli R.

Oncotarget. 2014 Jul 15;5(13):4722-31.

34.

Structure-based discovery of the first allosteric inhibitors of cyclin-dependent kinase 2.

Rastelli G, Anighoro A, Chripkova M, Carrassa L, Broggini M.

Cell Cycle. 2014;13(14):2296-305. doi: 10.4161/cc.29295. Epub 2014 Jun 9.

35.

Brassinin and its derivatives as potential anticancer agents.

Chripkova M, Drutovic D, Pilatova M, Mikes J, Budovska M, Vaskova J, Broggini M, Mirossay L, Mojzis J.

Toxicol In Vitro. 2014 Aug;28(5):909-15. doi: 10.1016/j.tiv.2014.04.002. Epub 2014 Apr 18.

PMID:
24747292
36.

DRAGO (KIAA0247), a new DNA damage-responsive, p53-inducible gene that cooperates with p53 as oncosuppressor. [Corrected].

Polato F, Rusconi P, Zangrossi S, Morelli F, Boeri M, Musi A, Marchini S, Castiglioni V, Scanziani E, Torri V, Broggini M.

J Natl Cancer Inst. 2014 Apr;106(4):dju053. doi: 10.1093/jnci/dju053. Epub 2014 Mar 20. Erratum in: J Natl Cancer Inst. 2014 Aug;106(8):dju199 doi:10.1093/jnci/dju199.

37.

Combination of the c-Met inhibitor tivantinib and zoledronic acid prevents tumor bone engraftment and inhibits progression of established bone metastases in a breast xenograft model.

Previdi S, Scolari F, Chilà R, Ricci F, Abbadessa G, Broggini M.

PLoS One. 2013 Nov 18;8(11):e79101. doi: 10.1371/journal.pone.0079101. eCollection 2013.

38.

Across the universe of K-RAS mutations in non-small-cell-lung cancer.

Piva S, Ganzinelli M, Garassino MC, Caiola E, Farina G, Broggini M, Marabese M.

Curr Pharm Des. 2014;20(24):3933-43. Review.

PMID:
24138715
39.

Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial.

Garassino MC, Martelli O, Broggini M, Farina G, Veronese S, Rulli E, Bianchi F, Bettini A, Longo F, Moscetti L, Tomirotti M, Marabese M, Ganzinelli M, Lauricella C, Labianca R, Floriani I, Giaccone G, Torri V, Scanni A, Marsoni S; TAILOR trialists.

Lancet Oncol. 2013 Sep;14(10):981-8. doi: 10.1016/S1470-2045(13)70310-3. Epub 2013 Jul 22.

PMID:
23883922
40.

Triple negative breast cancers have a reduced expression of DNA repair genes.

Ribeiro E, Ganzinelli M, Andreis D, Bertoni R, Giardini R, Fox SB, Broggini M, Bottini A, Zanoni V, Bazzola L, Foroni C, Generali D, Damia G.

PLoS One. 2013 Jun 25;8(6):e66243. doi: 10.1371/journal.pone.0066243. Print 2013.

41.

Non-hepatic tumors change the activity of genes encoding copper trafficking proteins in the liver.

Babich PS, Skvortsov AN, Rusconi P, Tsymbalenko NV, Mutanen M, Puchkova LV, Broggini M.

Cancer Biol Ther. 2013 Jul;14(7):614-24. doi: 10.4161/cbt.24594. Epub 2013 May 10.

42.

Zebularine partially reverses GST methylation in prostate cancer cells and restores sensitivity to the DNA minor groove binder brostallicin.

Sabatino MA, Geroni C, Ganzinelli M, Ceruti R, Broggini M.

Epigenetics. 2013 Jun;8(6):656-65. doi: 10.4161/epi.24916. Epub 2013 Jun 14.

43.

Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET--letter.

Rimassa L, Bruix J, Broggini M, Santoro A.

Clin Cancer Res. 2013 Aug 1;19(15):4290. doi: 10.1158/1078-0432.CCR-13-1321. Epub 2013 Jun 13. No abstract available.

44.

ALDH enzymatic activity and CD133 positivity and response to chemotherapy in ovarian cancer patients.

Ricci F, Bernasconi S, Porcu L, Erba E, Panini N, Fruscio R, Sina F, Torri V, Broggini M, Damia G.

Am J Cancer Res. 2013 Apr 3;3(2):221-9. Print 2013.

45.

Revisiting ovarian cancer preclinical models: implications for a better management of the disease.

Ricci F, Broggini M, Damia G.

Cancer Treat Rev. 2013 Oct;39(6):561-8. doi: 10.1016/j.ctrv.2013.01.005. Epub 2013 Feb 19. Review.

PMID:
23434073
46.

Evaluation of safety and efficacy of tivantinib in the treatment of inoperable or recurrent non-small-cell lung cancer.

Broggini M, Garassino MC, Damia G.

Cancer Manag Res. 2013;5:15-20. doi: 10.2147/CMAR.S29995. Epub 2013 Jan 17.

47.

To target or not to target, that is the question.

Garassino MC, Platania M, Broggini M, Torri V, De Braud F.

J Clin Oncol. 2013 Mar 20;31(9):1254. doi: 10.1200/JCO.2012.45.9818. Epub 2013 Jan 28. No abstract available.

48.

Seminars in clinical pharmacology: an introduction to MET inhibitors for the medical oncologist.

Fasolo A, Sessa C, Gianni L, Broggini M.

Ann Oncol. 2013 Jan;24(1):14-20. doi: 10.1093/annonc/mds520. Epub 2012 Oct 30. Review.

PMID:
23110808
49.

Serum depletion of holo-ceruloplasmin induced by silver ions in vivo reduces uptake of cisplatin.

Zatulovskiy EA, Skvortsov AN, Rusconi P, Ilyechova EY, Babich PS, Tsymbalenko NV, Broggini M, Puchkova LV.

J Inorg Biochem. 2012 Nov;116:88-96. doi: 10.1016/j.jinorgbio.2012.07.003. Epub 2012 Jul 8.

PMID:
23018271
50.

Combined inhibition of Chk1 and Wee1: in vitro synergistic effect translates to tumor growth inhibition in vivo.

Carrassa L, Chilà R, Lupi M, Ricci F, Celenza C, Mazzoletti M, Broggini M, Damia G.

Cell Cycle. 2012 Jul 1;11(13):2507-17. doi: 10.4161/cc.20899. Epub 2012 Jul 1.

PMID:
22713237

Supplemental Content

Loading ...
Support Center